

## **UPDATE**

06/06/2024

Fidelis Care Medicaid Preferred Drug List

Dear Provider,

Thank you for your partnership.

We have some important information to share with you.

At the **June 6<sup>th,</sup> 2024** Fidelis Care Pharmacy & Therapeutics meeting, it was decided that the following changes will be made to the **Fidelis Care Medicaid Preferred Drug List** (PDL), effective **9/01/2024**. Please review these changes carefully.

Key			
UPPER CASE = Brand Name Drugs	QL = Quantity Limit		
Lower case italics = Generic Drugs	ST = Step Therapy		
PDL = Preferred Drug List	AL = Age Limit		
PA = Prior Authorization	YOA = Years of Age		
SC = Safety Concerns	<b>LU</b> = Low Utilization		
PC = Pharmacoeconomic	<b>DD</b> = Discontinued Drug		
GA = Generic Available	CR = Clinical Removal		

Effective Date: 09/01/2024

Drug Name	Therapeutic Class	Change	PDL Alternative (if applicable)
ADDITIONS TO THE PDL			
dabigatran etexilate mesylate (Pradaxa)	Anticoagulants	Added to PDL with QL/DD	
Simlandi	TNF blockers	Added to PDL with PA; Update applicable PA criteria to include Simlandi as one of the preferred Humira biosimilars	
UTILIZATION MANAGEMENT CHANGES			



Trospium Chloride, acyclovir cream/ointment (Zovirax Cream/Ointment), Natroba (spinosad), Dovonex cream (calcipotriene cream), ciprofloxacin- dexamethasone otic suspension (Ciprodex Otic), calcipotriene ointment/solution, Amerge (naratriptan), Actos (pioglitazone), Actoplus Met (pioglitazone hcl- metformin)	Multiple	Removed EST	
adalimumab-ryvk	TNF Blockers	Manage at NDC, keep at Tier 9, updated WFD to N	
asenapine maleate (Saphris), pimecrolimus (Elidel), Absorbica (generics), Xhance (fluticasone propionate nasal spray)	Multiple	PA added, removed EST	
Xhance (fluticasone propionate nasal spray)	Nasal Agents	PA updated; Modify existing PA criteria to add triple step with two intranasal corticosteroids (INCs) and one intranasal saline agent to chronic rhinosinusitis without nasal polyps indication (CRSsNP)	
Remicade (infliximab)	Anti- inflammatory/Ga strointestinal Agents	PA updated; Update criteria to step brand Remicade through unbranded Remicade (after	



		preferred	
7 6 1 /: 61: :	Δ ('	biosimilars)	
Zymfentra ( <i>infliximab-</i>	Anti-	PA updated;	
dyyb)	inflammatory/Ga	Update Zymfentra	
	strointestinal	criteria to limit use	
	Agents	to members unable	
		to continue	
		receiving IV	
		infliximab infusions	
		due to healthcare	
Francis (acceptable)	Candiavaaavdan	access issues	
Entresto (sacubitril-	Cardiovascular	PA updated;	
valsartan)	Agents	Separate criteria	
		and require step	
	11 ( ' ' '	through Farxiga AG	
Udenyca	Hematopoietic	PA updated; Modify	
(pegfilgrastim-cbqv)	Agents	corresponding	
Nyvepria		clinical criteria to	
(pegfilgrastim-apgf)		co-prefer Udenyca	
Ziextenzo		and Nyvepria	
(pegfilgrastim-bmez)		(remove preference	
		of Ziextenzo).	
		Remove the	
		redirection to Zarxio	
0		from all indications	
Genotropin/Genotropi	Human Growth	PA updated;	
n Miniquick	Hormone	Update criteria to	
(somatropin)		co-prefer Zomacton	
		and Omnitrope Vial;	
		if preferred drugs are not available	
		due to a shortage,	
		use Omnitrope	
		Cartridge; add	
		Skytrofa to Clinical	
	DEMOVALO I	criteria	
REMOVALS FROM THE PDL			
Prudoxin/Zonalon	Dermatologicals	Removed from PDL, removed EST	
cream (doxepin) Janumet/Janumet XR	A ptidich atios	,	
	Antidiabetics	Removed from	
(sitagliptin-metformin)	Llloon	PDL, removed EST	
First-Lansoprazole	Ulcer	Removed from	
	drugs/antispasm	PDL, removed EST	



	odics/anticholin ergics		
Denavir (penciclovir)	Dermatologicals	Removed from	
-	_	PDL, removed EST	
calcipotriene foam	Dermatologicals	Removed from	
	_	PDL, removed EST	

If you have any questions, Fidelis Care's Pharmacy Help Desk is available to assist providers at **1-888-453-2534**.

Thank you for your quality care of Fidelis Care Medicaid members.

Sincerely, Fidelis Care Pharmacy